Last edition
News about "ES-SCLC therapy"
SN BioScience Doses First Patient in Phase 1b/2 Clinical Trial of SNB-101
SN BioScience initiates first patient dosing in a global phase 1b/2 trial of SNB-101, a nanoparticle anticancer therapy for Small Cell Lung Cancer (SCLC).
ES-SCLC Therapy | 16/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members